Content about Perrigo

March 26, 2014

Perrigo announced that its Nutritionals segment is partnering with KanPak to manufacture store brand adult nutritional drinks comparable to Ensure products.

DUBLIN — Perrigo on Wednesday announced that its Nutritionals segment is partnering with KanPak to manufacture store brand adult nutritional drinks comparable to Ensure products. KanPak is a supplier of beverages and desserts using aseptic processing technology. 

March 18, 2014

The Consumer Healthcare Products Association on Tuesday announced the members of the CHPA Educational Foundation Board during the association’s Annual Executive Conference held here.

AMELIA ISLAND, Fla. — The Consumer Healthcare Products Association on Tuesday announced the members of the CHPA Educational Foundation Board during the association’s Annual Executive Conference held here.

March 13, 2014

Perrigo announced the launch of methazolamide tablets, the generic version of Neptazane tablets. The product is a component of the rights the company received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals and its affiliates last year.

DUBLIN — Perrigo announced the launch of methazolamide tablets, the generic version of Neptazane tablets. The product is a component of the rights the company received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals and its affiliates last year.

March 10, 2014

Two Rx-to-OTC switches in the past year may serve as a harbinger of what the Food and Drug Administration will consider “switch” worthy.

Two Rx-to-OTC switches in the past year may serve as a harbinger of what the Food and Drug Administration will consider “switch” worthy. They both address chronic care needs, and they both represent first of their kind medicines to the nonprescription aisle.

February 28, 2014

Perrigo on Friday announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global for $51 million in cash.

DUBLIN — Perrigo on Friday announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global for $51 million in cash. 

The products are primarily sold through the mass retail channel and include the Herron range of analgesics, vitamins and supplements. This basket of products is expected to generate at least $20 million in annual revenue.

January 24, 2014

Perrigo announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets.

DUBLIN — Perrigo Co. announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets — in 1-mg and 2-mg strengths. The company has started shipment of the drug. Perrigo previously launched the 0.5-mg strength in 2013.

January 15, 2014

Perrigo on Tuesday announced that it has received final approval for its abbreviated new drug application for fluocinonide cream 0.1%, the generic equivalent to prescription-only Vanos Cream 0.1%.

DUBLIN — Perrigo on Tuesday announced that it has received final approval for its abbreviated new drug application for fluocinonide cream 0.1%, the generic equivalent to prescription-only Vanos Cream 0.1%. 

Perrigo was awarded 180-days of generic drug exclusivity as it was the first company to submit an ANDA containing a paragraph IV certification. Perrigo had previously resolved litigation with the brand and has commenced shipment of the product.

December 18, 2013

Perrigo has finalized its acquisition of Elan Corp., Perrigo said Wednesday.

DUBLIN — Perrigo has finalized its acquisition of Elan Corp., Perrigo said Wednesday.

The Michigan-based maker of branded and generic prescription and OTC drugs announced last week that the Irish High Court had approved its $8.6 billion deal to buy Ireland-based Elan, the last regulatory hurdle it had to clear before finalizing the deal, which it announced in July.

December 13, 2013

The Irish High Court has approved Perrigo's pending acquisition of Irish drug maker Elan, the companies said Friday.

ALLEGAN, Mich. — The Irish High Court has approved Perrigo's pending acquisition of Irish drug maker Elan, the companies said Friday.

November 22, 2013

The shareholders of Elan Corp. approved the acquisition of the company by Perrigo Co. at two special meetings.

DUBLIN — The shareholders of Elan Corp. approved the acquisition of the company by Perrigo Co. at two special meetings.

As previously announced earlier this year, Perrigo and Elan entered into an agreement under which the two companies will combine to form New Perrigo, an entirely new company incorporated in Ireland. The closing of the deal remains subject to approval by the Irish High Court and is expected to occur by the end of the year.

November 20, 2013

Drug maker Perrigo has filed with the Food and Drug Administration for approval of a generic topical ointment for treating acne in adolescents and adults, the company said Wednesday.

ALLEGAN, Mich. — Drug maker Perrigo has filed with the Food and Drug Administration for approval of a generic topical ointment for treating acne in adolescents and adults, the company said Wednesday.

Perrigo said it filed for approval of clindamycin phosphate and benzoyl peroxide gel in the 1.2%/2.5% strengths. The drug is used to treat acne in patients 12 years and older.

November 4, 2013

Perrigo on Friday initiated a voluntary, nationwide product recall to the retail level of 18 batches of its acetaminophen infant suspension liquid.

ALLEGAN, Mich. —  Perrigo on Friday initiated a voluntary, nationwide product recall to the retail level of 18 batches of its acetaminophen infant suspension liquid, 160 mg/5 mL, sold in 2 oz. and 4 oz. bottles with syringes in a box because of the remote potential that a small number of packages might contain an oral dosing syringe without dose markings. 

September 23, 2013

The Food and Drug Administration has approved a drug made by Perrigo Co. for treating heart disease, the company said Monday.

ALLEGAN, Mich. — The Food and Drug Administration has approved a drug made by Perrigo Co. for treating heart disease, the company said Monday.

The FDA approved Perrigo's nitroglycerin lingual spray in the 400-mcg-per-spray strength. The drug is used to relieve attacks of or prevent angina pectoris due to coronary artery disease.

September 20, 2013

Perrigo Co. has hired a former Food and Drug Administration official for its regulatory department, the drug maker said.

ALLEGAN, Mich. — Perrigo Co. has hired a former Food and Drug Administration official for its regulatory department, the drug maker said Friday.

The Allegan, Mich.-based drug maker announced the appointment of Keith Webber as head of regulatory review, a position in which he will start on Oct. 21. Webber previously served as acting director of the FDA's Office of Pharmaceutical Science, part of the Center for Drug Evaluation and Research, which regulates prescription and OTC drugs. He also served as director of the Office of Generic Drugs.

September 10, 2013

Perrigo announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for cetirizine hydrochloride oral solution USP, 1 mg/mL, bubble gum flavored, the store brand equivalent to Children's Zyrtec Allergy Syrup.

ALLEGAN, Mich. — Perrigo on Tuesday announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for cetirizine hydrochloride oral solution USP, 1 mg/mL, bubble gum flavored, the store brand equivalent to Children's Zyrtec Allergy Syrup. Perrigo expects to begin shipments of the product during the upcoming cough/cold/flu season.

August 12, 2013

Perrigo Co. announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Scalp Oil, and fluocinolone acetonide topical oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Body Oil.

ALLEGAN, Mich. — Perrigo Co. today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Scalp Oil, and fluocinolone acetonide topical oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Body Oil. Perrigo expects to begin shipments of both products next month.

August 12, 2013

Teva Pharmaceutical and Perrigo Co. announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the United States, and both companies will equally share in the cost and profitability of the product in the country.

JERUSALEM and ALLEGAN, Mich. — Teva Pharmaceutical Industries Ltd., and Perrigo Co. today announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the United States, and both companies will equally share in the cost and profitability of the product in the country. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

July 31, 2013

The Food and Drug Administration has approved a Perrigo generic drug for treating dermatitis, the company said Wednesday.

ALLEGAN, Mich. — The Food and Drug Administration has approved a Perrigo generic drug for treating dermatitis, the company said Wednesday.

Perrigo announced the FDA approval of fluticasone propionate lotion in the 0.05% strength. The drug is a generic version of Fougera Pharmaceuticals division PharmaDerm's Cutivate and is used to treat inflammatory and pruritic manifestations of atopic dermatitis in patients ages 1 year and older.

The drug has annual sales of about $19 million, according to Symphony Health Solutions.

 

July 29, 2013

U.S.-based drug maker Perrigo Co. will buy Ireland's Elan Corp. for $8.6 billion, the companies said.

ALLEGAN, Mich. — U.S.-based drug maker Perrigo Co. will buy Ireland's Elan Corp. for $8.6 billion, the companies said Monday.

Elan is best known for the multiple sclerosis treatment Tysabri (natalizumab), marketed and distributed by Biogen Idec. Perrigo manufactures various branded and generic prescription and OTC drugs. A previously announced deal, whereby New York-based Royalty Pharma would acquire the Dublin-based drug maker, fell apart last month after Elan shareholders voted in favor of a share-buyback plan.

July 19, 2013

Perrigo announced the tentative approval for repaglinide tablets, a generic version of Novo Nordisk's Prandin, used to treat Type 2 diabetes.

ALLEGAN, Mich. – The Food and Drug Administration has given tentative approval to a generic diabetes drug.

Perrigo Co. announced the tentative approval for repaglinide tablets, a generic version of Novo Nordisk's Prandin, used to treat Type 2 diabetes.

June 25, 2013

Tyco Integrated Security on Tuesday announced it has teamed up with Perrigo Nutritionals to develop a theft-resistant infant formula container.

BOCA RATON, Fla. — Tyco Integrated Security on Tuesday announced it has teamed up with Perrigo Nutritionals to develop a theft-resistant infant formula container. Baby formula frequently tops the list as one of the most commonly stolen products, and according to last year’s National Retail Security Survey results conducted by the University of Florida, the supermarket and grocery industry had the highest total shrinkage percentages of all retail segments.

June 24, 2013

Perrigo on Monday promoted Emily Hiller to assistant category manager for the category management team at Perrigo Nutritionals in Gordonsville, Va.

ALLEGAN, Mich. — Perrigo on Monday promoted Emily Hiller to assistant category manager for the category management team at Perrigo Nutritionals in Gordonsville, Va. In this role, Hiller will be responsible for developing category overviews to support corporate and customer specific presentations and product documentation. She also will develop direct mail and e-coupon programs, support social media projects and track category conversions.

June 17, 2013

Perrigo Co. will pay up to $129 million to buy Fera Pharmaceuticals' portfolio of ophthalmic products, Perrigo said.

ALLEGAN, Mich. — Perrigo Co. will pay up to $129 million to buy Fera Pharmaceuticals' portfolio of ophthalmic products, Perrigo said Monday.

Perrigo said the acquisition from Locust Valley, N.Y.-based Fera included an upfront payment of $93 million and milestone payments of about $36 million. The products include generic ophthalmic sterile ointments and solutions and generated sales of more than $30 million in 2012.

May 29, 2013

The Food and Drug Administration has approved a generic drug for incontinence made by Perrigo Co., the drug maker said.

ALLEGAN, Mich. — The Food and Drug Administration has approved a generic drug for incontinence made by Perrigo Co., the drug maker said Wednesday.

Perrigo announced the approval of trospium chloride extended-release capsules in the 60 mg strength, a once-daily treatment for overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. The drug is a generic version of Allergan's Sanctura XR, which has annual sales of $54 million, according to Symphony Health Solutions.

May 13, 2013

Perrigo on Monday announced it has kicked off a broad industry marketing and communications campaign to raise awareness for, and consumer confidence in, generic over-the-counter store-brand medications.

ALLEGAN, Mich. — Perrigo on Monday announced it has kicked off a broad industry marketing and communications campaign to raise awareness for, and consumer confidence in, generic over-the-counter store-brand medications.